AI-Designed Lung Fibrosis Pill Enters Phase III Trial With 320 Patients
Insilico Medicine's AI-discovered oral drug Rentosertib enters final-stage testing for a deadly, progressive lung disease with no cure.
Summary
Insilico Medicine has launched a Phase III clinical trial of Rentosertib, an oral once-daily pill targeting TNIK, a protein implicated in idiopathic pulmonary fibrosis (IPF). IPF is a fatal lung-scarring disease with limited treatment options. The trial will enroll 320 patients across 47 centers in China over 52 weeks, measuring lung function decline as the primary endpoint. Notably, Rentosertib was discovered entirely using Insilico's AI drug-discovery platform, making it a landmark test of whether AI-generated medicines can succeed in late-stage human trials. Earlier Phase IIa data showed patients on the 60 mg dose gained an average of 98.4 mL in forced vital capacity at 12 weeks — a meaningful signal in a disease where lung function typically deteriorates steadily.
Detailed Summary
Idiopathic pulmonary fibrosis is a progressive, irreversible scarring of lung tissue that steadily robs patients of their ability to breathe. Median survival after diagnosis is just three to five years, and existing approved therapies only slow — not stop — the decline. Any new drug that meaningfully preserves lung function would represent a major advance for patients and a proof point for AI-driven drug discovery.
Insilico Medicine has now initiated a Phase III trial of Rentosertib, an orally administered small-molecule inhibitor of TNIK (TRAF2- and NCK-interacting kinase). The randomized, double-blind, placebo-controlled study will enroll 320 patients across 47 clinical centers in China. Participants will receive once-daily Rentosertib for 52 weeks, with the primary endpoint being the annual rate of decline in forced vital capacity — the standard measure of how much air the lungs can expel.
What makes Rentosertib scientifically notable is its origin. The drug target, TNIK, was identified by Insilico's PandaOmics AI platform, and the molecule itself was generated by Chemistry42, another AI system. This makes Rentosertib one of the first AI-designed drugs to reach Phase III, turning this trial into a high-stakes test for the entire field of computational drug discovery.
Prior Phase IIa data from the GENESIS-IPF study — 71 patients — showed that the 60 mg once-daily dose produced a mean FVC improvement of +98.4 mL at 12 weeks while meeting its primary safety and tolerability objectives. The FDA granted Rentosertib orphan drug designation in February 2023, recognizing the unmet need in this rare disease.
The trial is still investigational and no regulatory approval has been granted. Results are expected after the 52-week treatment period concludes, likely in 2027 or 2028. If successful, Rentosertib could become both a new IPF therapy and a watershed moment validating AI-generated medicines.
Key Findings
- Phase III trial enrolling 320 IPF patients to test once-daily Rentosertib over 52 weeks across 47 China centers.
- Phase IIa data showed a +98.4 mL mean FVC gain at 12 weeks in the 60 mg dose arm — a clinically meaningful signal.
- Rentosertib is among the first AI-designed drugs to reach Phase III, validating Insilico's Pharma.AI platform.
- FDA granted Rentosertib orphan drug designation for IPF in February 2023.
- Primary endpoint is annual FVC decline rate; key secondary endpoint is time to first disease progression event.
Methodology
This is a news report summarizing a company-issued trial initiation announcement, published by Longevity.Technology, a credible longevity-focused outlet. Evidence basis is Phase IIa data from 71 patients and company disclosures; no peer-reviewed Phase III data yet exists. Claims originate from Insilico Medicine and should be verified against ClinicalTrials.gov registry entries.
Study Limitations
Phase IIa data came from only 71 patients in a study not powered for efficacy, making the +98.4 mL FVC finding preliminary. All data presented derives from the company; independent peer-reviewed publication of Phase IIa results should be confirmed. The Phase III trial is conducted solely in China, which may limit generalizability to other populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: